Chungbuk National University Hospital
Cheongju-si, South Korea
NCT Number: NCT04500132
Prevention of COVID-19 infection to severe pneumonea or ARDS
Looking for future studies?
Notify Me19 year and older
All sexes
Interventional
Phase 2
Cheongju-si, South Korea
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
EC-18 QD
Placebo EC-18 QD
Time frame: 14 days after starting IP administration
Enzychem Lifesciences Corporation
Industry
Phase 2, Multi-center, Randomized, Double-blind, Placebo- Controlled Study to Evaluate the Safety and Efficacy of EC-18 in COVID-19 Infection to Pneumonia
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07128069
COVID-19, Coronaviridae Infections
Chicago, Illinois, United States
View Trial DetailsNCT07222384
COVID-19, Coronaviridae Infections
Palo Alto, California, United States
View Trial DetailsNCT05543616
COVID-19, Coronaviridae Infections
Birmingham, Alabama, United States
View Trial DetailsNCT05732116
COVID-19, Coronaviridae Infections
Ningbo, Zhejiang, China
View Trial Details